[What should we remember from 2020?]

[1]  R. Labianca,et al.  Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. , 2020, The Lancet. Oncology.

[2]  M. Friedlander,et al.  234O Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1 , 2020, Annals of Oncology.

[3]  A. Reuss,et al.  Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer – final analysis of AGO DESKTOP III/ENGOT- ov20 , 2020, Geburtshilfe und Frauenheilkunde.

[4]  D. Olmos.  IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC) , 2020 .

[5]  F. Saad,et al.  Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[6]  K. Hoang-Xuan,et al.  Central nervous system involvement in Erdheim-Chester disease , 2020, Neurology.

[7]  T. Powles,et al.  697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE) , 2020 .

[8]  R. Advani,et al.  Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. , 2020, The Lancet. Haematology.

[9]  J. Ajani,et al.  LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study , 2020 .

[10]  C. Tournigand,et al.  LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial , 2020 .

[11]  M. Burotto,et al.  696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial , 2020 .

[12]  T. Powles,et al.  LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361 , 2020 .

[13]  A. Letai,et al.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.

[14]  N. Magné,et al.  Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study. , 2020, The Lancet. Oncology.

[15]  T. Powles,et al.  Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. , 2020 .

[16]  D. Vernerey,et al.  Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE. , 2020, Bulletin du cancer.

[17]  P. Gibbs,et al.  Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. , 2020, Journal of Clinical Oncology.

[18]  J. Bourhis,et al.  TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). , 2020 .

[19]  A. Oza,et al.  Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. , 2020 .

[20]  Y. Bang,et al.  Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01). , 2020 .

[21]  M. Weller,et al.  Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma , 2020, JAMA oncology.

[22]  K. Yonemori,et al.  NivoCUP: An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary. , 2020 .

[23]  A. Grothey,et al.  A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. , 2020, Journal of Clinical Oncology.

[24]  H. Putter,et al.  Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial. , 2020, Journal of Clinical Oncology.

[25]  T. Conroy,et al.  Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. , 2020, Journal of Clinical Oncology.

[26]  M. Galsky,et al.  Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial , 2020, The Lancet.

[27]  C. Balañà,et al.  A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01). , 2020, Neuro-oncology.

[28]  G. Dunn,et al.  A review of glioblastoma immunotherapy , 2020, Journal of Neuro-Oncology.

[29]  J. Byrd,et al.  Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial , 2020, The Lancet.

[30]  Michael L. Wang,et al.  KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. , 2020, The New England journal of medicine.

[31]  E. Bruera,et al.  Models of Palliative Care Delivery for Patients With Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  N. Magné,et al.  [2019 international oncology news: A compendium]. , 2020, Bulletin du cancer.

[33]  R. Stupp,et al.  Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis , 2020, International journal of cancer.

[34]  D. Pe’er,et al.  Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma , 2019, Nature Medicine.

[35]  Matthew D. Young,et al.  Embryonal precursors of Wilms tumor , 2019, Science.

[36]  A. Rosenwald,et al.  Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial , 2019, The Lancet.

[37]  Hung-Ming Wang,et al.  Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.

[38]  R. Advani,et al.  Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. , 2019, Blood.

[39]  B. Chauffert,et al.  A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04) , 2019, Annals of Oncology.

[40]  Andrew L Beers,et al.  Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma , 2019, Clinical Cancer Research.

[41]  P. Sonneveld,et al.  Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study , 2019, The Lancet.

[42]  A. Hagenbeek,et al.  Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). , 2019, The Lancet. Haematology.

[43]  I. Flinn,et al.  Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. , 2019, Blood.

[44]  E. Bruera,et al.  Improving patient and caregiver outcomes in oncology: Team‐based, timely, and targeted palliative care , 2018, CA: a cancer journal for clinicians.

[45]  R. Collins,et al.  Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML , 2018, The New England journal of medicine.

[46]  C. Massard,et al.  Prise en charge des carcinomes de primitif inconnu en 2016 , 2016 .

[47]  T. Kipps,et al.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.

[48]  T. Kipps,et al.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. , 2015, The New England journal of medicine.

[49]  N. Pavlidis,et al.  Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  P. Petrow,et al.  Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.